Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
This is a Phase 1 dose escalation study to assess the safety and tolerability of subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage solid tumors. Once the MTD has been determined up to 12 patients will be treated at this dose level, to further characterize treatment emergent adverse events (TEAEs).
Age
21 - 85 years
Sex
ALL
Healthy Volunteers
No
HonorHealth Research Institute
Scottsdale, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Start Date
February 1, 2016
Primary Completion Date
December 16, 2019
Completion Date
December 16, 2019
Last Updated
January 27, 2020
32
ACTUAL participants
SDX-7320
DRUG
Lead Sponsor
SynDevRx, Inc.
NCT05039801
NCT05372640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions